Rehmann Capital Advisory Group Has $884,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Rehmann Capital Advisory Group boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 15.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,683 shares of the biopharmaceutical company’s stock after acquiring an additional 231 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Regeneron Pharmaceuticals were worth $884,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Founders Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after purchasing an additional 538 shares in the last quarter. Sepio Capital LP raised its position in shares of Regeneron Pharmaceuticals by 33.1% during the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after acquiring an additional 842 shares during the last quarter. PGGM Investments raised its position in shares of Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock worth $16,255,000 after acquiring an additional 955 shares during the last quarter. Finally, Generate Investment Management Ltd bought a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $6,300,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.9%

NASDAQ REGN opened at $584.74 on Thursday. The company has a market cap of $61.98 billion, a price-to-earnings ratio of 14.74, a P/E/G ratio of 1.81 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $959.60. The business has a 50 day moving average price of $576.17 and a 200-day moving average price of $562.42. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 earnings per share. Regeneron Pharmaceuticals’s revenue was up 3.6% compared to the same quarter last year. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of analyst reports. Citigroup raised their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Sanford C. Bernstein raised their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price objective for the company. in a research report on Friday, August 1st. Finally, UBS Group reiterated a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.